Search

Displaying results 2711 - 2720 of 10000 in total
  1. Drug

    Ginkgo biloba

    go.drugbank.com/drugs/DB01381
    ApprovedInvestigationalNutraceutical

    [A232389] Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized extract of _Ginkgo biloba_ (EGb) 761 (EGb761), which was developed by a German pharmaceutical company in … [A232379] _Ginkgo folium_, the leaf extract of _Ginkgo biloba_, is considered an anti-dementia drug by the World Health Organization.[A232389]

    Products: EXTRACTO DE GINKO BILOBA AL 24 % EQUIVALENTE A 9.6 MG DE GLICOSIDOS FLAVONOIDES.
  2. Drug

    Lipegfilgrastim

    go.drugbank.com/drugs/DB13200
    Approved

    It aims to reduce the duration of neutropenia and the incidence of febrile neutropenia. … Granulocyte colony-stimulating factors (G-CSFs) were introduced in the 1980's to the clinical setting to stimulate neutrophil proliferation and differentiation, thereby reducing the duration and severity

  3. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. … [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and

    Categories: Calcitonin Gene-Related Peptide Receptor Antagonists
  4. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108] … Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist.

  5. Drug

    Romosozumab

    go.drugbank.com/drugs/DB11866
    ApprovedInvestigational

    to other osteoperosis therapies[L9554]. … Romosozumab is marketed in the United States by Amgen under the brand name Evinity[L5921]. Romosozumab was granted FDA approval on April 9,2019[L5921].

  6. Drug

    Nadolol

    go.drugbank.com/drugs/DB01203
    ApprovedInvestigational

    Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure. … [L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and

  7. Drug

    Butalbital

    go.drugbank.com/drugs/DB00241
    ApprovedIllicit

    to general anesthesia. … Due to these risks, the use of butalbital-containing combination products is typically limited for use only in cases where other medications are deemed ineffective and such usage is advised to be carefully

  8. Drug

    Naldemedine

    go.drugbank.com/drugs/DB11691
    ApprovedInvestigational

    Naldemedine is an opioid receptor antagonist [FDA Label]. … Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation.

    Categories: Peripheral Opioid Receptor Antagonists
  9. Drug

    Oxaliplatin

    go.drugbank.com/drugs/DB00526
    ApprovedInvestigational

    [A797] However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. … [A260396] However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic

  10. Drug

    Ferric sulfate

    go.drugbank.com/drugs/DB11171
    Approved

    [A32355, A32356] By the FDA, ferric sulfate is a direct food substance affirmed in the GRAS category (Generally Recognized As Safe).[L2003] … Ferric sulfate has the molecular formula of Fe2SO4, and it is a dark brown or yellow chemical agent with acidic properties. It is produced by the reaction of sulfuric acid and an oxidizing agent.